190 related articles for article (PubMed ID: 26170152)
1. 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry.
Bruder O; Schneider S; Pilz G; van Rossum AC; Schwitter J; Nothnagel D; Lombardi M; Buss S; Wagner A; Petersen S; Greulich S; Jensen C; Nagel E; Sechtem U; Mahrholdt H
J Cardiovasc Magn Reson; 2015 Jul; 17(1):58. PubMed ID: 26170152
[TBL] [Abstract][Full Text] [Related]
2. Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry.
Bruder O; Schneider S; Nothnagel D; Pilz G; Lombardi M; Sinha A; Wagner A; Dill T; Frank H; van Rossum A; Schwitter J; Nagel E; Senges J; Sabin G; Sechtem U; Mahrholdt H
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1171-6. PubMed ID: 22093267
[TBL] [Abstract][Full Text] [Related]
3. Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients.
Uhlig J; Lücke C; Vliegenthart R; Loewe C; Grothoff M; Schuster A; Lurz P; Jacquier A; Francone M; Zapf A; Schülke C; ; May MS; Bremerich J; Lotz J; Gutberlet M;
Eur Radiol; 2019 Jul; 29(7):3686-3695. PubMed ID: 31041566
[TBL] [Abstract][Full Text] [Related]
4. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
5. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
Aran S; Shaqdan KW; Abujudeh HH
Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
[TBL] [Abstract][Full Text] [Related]
6. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
7. European Cardiovascular Magnetic Resonance (EuroCMR) registry--multi national results from 57 centers in 15 countries.
Bruder O; Wagner A; Lombardi M; Schwitter J; van Rossum A; Pilz G; Nothnagel D; Steen H; Petersen S; Nagel E; Prasad S; Schumm J; Greulich S; Cagnolo A; Monney P; Deluigi CC; Dill T; Frank H; Sabin G; Schneider S; Mahrholdt H
J Cardiovasc Magn Reson; 2013 Jan; 15(1):9. PubMed ID: 23331632
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
Nacif MS; Arai AE; Lima JA; Bluemke DA
J Cardiovasc Magn Reson; 2012 Feb; 14(1):18. PubMed ID: 22376193
[TBL] [Abstract][Full Text] [Related]
9. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
[TBL] [Abstract][Full Text] [Related]
10. Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations.
Granata V; Cascella M; Fusco R; dell'Aprovitola N; Catalano O; Filice S; Schiavone V; Izzo F; Cuomo A; Petrillo A
Biomed Res Int; 2016; 2016():3918292. PubMed ID: 27652261
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors.
Murphy KP; Szopinski KT; Cohan RH; Mermillod B; Ellis JH
Acad Radiol; 1999 Nov; 6(11):656-64. PubMed ID: 10894068
[TBL] [Abstract][Full Text] [Related]
12. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
Edwards BJ; Laumann AE; Nardone B; Miller FH; Restaino J; Raisch DW; McKoy JM; Hammel JA; Bhatt K; Bauer K; Samaras AT; Fisher MJ; Bull C; Saddleton E; Belknap SM; Thomsen HS; Kanal E; Cowper SE; Abu Alfa AK; West DP
Br J Radiol; 2014 Oct; 87(1042):20140307. PubMed ID: 25230161
[TBL] [Abstract][Full Text] [Related]
13. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
14. Acute Reactions to Gadolinium-Based Contrast Agents in a Pediatric Cohort: A Retrospective Study of 16,237 Injections.
McDonald JS; Larson NB; Kolbe AB; Hunt CH; Schmitz JJ; Kallmes DF; McDonald RJ
AJR Am J Roentgenol; 2021 May; 216(5):1363-1369. PubMed ID: 32755216
[No Abstract] [Full Text] [Related]
15. Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System.
Bendszus M; Roberts D; Kolumban B; Meza JA; Bereczki D; San-Juan D; Liu BP; Anzalone N; Maravilla K
Invest Radiol; 2020 Mar; 55(3):129-137. PubMed ID: 31917762
[TBL] [Abstract][Full Text] [Related]
16. Immediate hypersensitivity reaction to gadolinium-based MR contrast media.
Jung JW; Kang HR; Kim MH; Lee W; Min KU; Han MH; Cho SH
Radiology; 2012 Aug; 264(2):414-22. PubMed ID: 22550309
[TBL] [Abstract][Full Text] [Related]
17. Adverse reactions to gadolinium contrast media: a review of 36 cases.
Murphy KJ; Brunberg JA; Cohan RH
AJR Am J Roentgenol; 1996 Oct; 167(4):847-9. PubMed ID: 8819369
[TBL] [Abstract][Full Text] [Related]
18. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Runge VM; Armstrong MR; Barr RG; Berger BL; Czervionke LF; Gonzalez CF; Halford HH; Kanal E; Kuhn MJ; Levin JM; Low RN; Tanenbaum LN; Wang AM; Wong W; Yuh WT; Zoarski GH
Invest Radiol; 2001 Feb; 36(2):65-71. PubMed ID: 11224753
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Runge VM; Parker JR; Donovan M
Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
[TBL] [Abstract][Full Text] [Related]
20. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
Runge VM
Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
